Loading...
XLON
ONC
Market cap16kUSD
Mar 17, Last price  
0.01GBP
Name

Oncimmune Holdings PLC

Chart & Performance

D1W1MN
No data to show
P/E
0.31
P/S
1.11
EPS
0.04
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-14.87%
Revenues
1m
-70.15%
1,535,0001,057,0001,345,000430,000215,000240,000171,000509,0003,722,0003,859,0001,152,000
Net income
4m
P
-3,016,000-1,412,000-2,013,000-8,442,000-5,023,000-6,310,000-8,012,000-8,459,000-4,628,000-9,512,0004,104,000
CFO
-7m
L+9.34%
-2,985,000-2,149,000-1,520,000-3,179,000-4,279,000-6,101,000-7,359,000-8,903,000-4,527,000-6,211,000-6,791,000
Earnings
May 19, 2025

Profile

Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.
URL
https://oncimmune.com/
IPO date
May 18, 2016
Employees
52
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑082022‑052021‑052020‑052019‑052018‑052017‑052016‑052015‑05
Income
Revenues
1,152
-70.15%
3,859
3.68%
Cost of revenue
5,394
10,971
Unusual Expense (Income)
NOPBT
(4,242)
(7,112)
NOPBT Margin
Operating Taxes
223
(17)
Tax Rate
NOPAT
(4,465)
(7,095)
Net income
4,104
-143.15%
(9,512)
105.53%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,095
142
BB yield
-12.44%
-0.23%
Debt
Debt current
332
7,914
Long-term debt
4,969
3,567
Deferred revenue
57
Other long-term liabilities
1,284
2,000
Net debt
2,575
8,951
Cash flow
Cash from operating activities
(6,791)
(6,211)
CAPEX
(31)
(504)
Cash from investing activities
11,583
(504)
Cash from financing activities
(3,015)
987
FCF
(2,846)
(1,912)
Balance
Cash
3,209
2,530
Long term investments
(483)
Excess cash
2,668
2,337
Stockholders' equity
(42,026)
(78,916)
Invested Capital
49,268
88,841
ROIC
ROCE
EV
Common stock shares outstanding
72,575
64,547
Price
0.23
-76.21%
0.98
-53.24%
Market cap
16,837
-73.25%
62,933
-53.26%
EV
19,412
71,926
EBITDA
(3,977)
(5,683)
EV/EBITDA
Interest
516
943
Interest/NOPBT